secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001104659-25-049581
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment
-------------------------------------------------------------------------------

- Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
- Cash, equivalents restricted cash $1.8M at March 31, 2025; R&D $1.3M, G&A $1.8M.
- Submitted IND amendment for Phase 3b NurOwn trial (ENDURANCE) targeting ~200 early ALS patients with SPA.
- Trial listed on ClinicalTrials.gov (NCT06973629) with 15 clinical sites; data at ISCT and ALS Summit.
- Conference call rescheduled to May 19, 2025 at 8:30 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/0001104659-25-049581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925049581/tm2515198d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-049581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer